List of works - Catherine Roche-Lestienne

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

scientific article published in May 2003

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

scientific article

Acute megakaryoblastic leukemia with der(7)t(5;7)(q11;p11 approximately p12) associated with Down syndrome: a fourth case report

scientific article published on 01 September 2006

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis

scientific article

CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

scientific article published on 14 February 2015

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

scientific article published on 17 August 2011

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

scientific article published on 01 October 2008

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

scientific article published on 01 September 2007

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

scientific article

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

scientific article

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies.

scientific article published on 13 December 2011

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?

scientific article

Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).

scientific article

Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance.

scientific article published on 6 September 2014

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia

scientific article

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

scientific article

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

scientific article published on 27 January 2020

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

scientific article published in January 2005

Familial myeloid malignancies with germline TET2 mutation

scientific article published on 11 December 2019

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.

scientific article published in August 2011

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

scientific article

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients

scientific article published on 03 August 2010

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

scientific article published on 8 April 2009

Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition

scientific article published in May 2005

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

scientific article

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

scientific article published on 20 May 2010

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

scientific article

Isolated tetrasomy 13: a fifth case report of a rare chromosome abnormality associated with poorly differentiated acute myeloid leukemia

scientific article published on 01 July 2006

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

scientific article published on 13 February 2007

MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype

scientific article published on 6 March 2018

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

scientific article published on 26 March 2013

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

scientific article published in April 2008

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

scientific article

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

scientific article published on 03 June 2011

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

scientific article published on 01 June 2006

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

scientific article

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

scientific article published on 3 October 2016

Origin of resistance to Imatinib mesylate: lessons learned from this experience

scientific article published in December 2004

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

scientific article published on 17 January 2008

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies

scientific article

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

scientific article

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

scientific article published in February 2004

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

scientific article

Targeting MYC in multiple myeloma

scientific article published on 22 February 2018

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

scientific article published on 22 August 2016

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

scientific article published on 28 May 2013

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

scientific article published on 24 October 2016

The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype

scientific article

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

scientific article published on 6 November 2008

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

scientific article published on 01 February 2007

WAGR syndrome and congenital hypothyroidism in a child with a Mosaic 11p13 deletion.

scientific article published on 11 April 2017

[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]

scientific article published on 09 August 2006

List of works by Catherine Roche-Lestienne

A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.

Acquisition of genomic events leading to lymphoblastic transformation in a rare case of myeloproliferative neoplasm with BCR-JAK2 fusion transcript.

Acute megakaryoblastic leukemia with der(7)t(5;7)(q11;p11 approximately p12) associated with Down syndrome: a fourth case report

Bone morphogenetic protein antagonist gene NOG is involved in myeloproliferative disease associated with myelofibrosis

CD3-CD4+ lymphoid variant of hypereosinophilic syndrome: nodal and extranodal histopathological and immunophenotypic features of a peripheral indolent clonal T-cell lymphoproliferative disorder

Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study

Chronic myeloproliferative disorder with t(8;22)(p11;q11) can mime clonal cytogenetic evolution of authentic chronic myelogeneous leukemia

Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

Coexistence of AML1/RUNX1 and BCR-ABL point mutations in an imatinib-resistant form of CML.

Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index

Correction: Refinement of 1p36 Alterations Not Involving PRDM16 in Myeloid and Lymphoid Malignancies.

Cryptic and partial deletions of PRDM16 and RUNX1 without t(1;21)(p36;q22) and/or RUNX1-PRDM16 fusion in a case of progressive chronic myeloid leukemia: a complex chromosomal rearrangement of underestimated frequency in disease progression?

Cytogenetics in the management of "chronic myeloid leukemia": an update by the Groupe francophone de cytogénétique hématologique (GFCH).

Detection of dicentric chromosome (9;20) in paediatric B-cell acute lymphoblastic leukaemia: prognostic significance.

Diagnosis of intrachromosomal amplification of chromosome 21 (iAMP21) by molecular cytogenetics in pediatric acute lymphoblastic leukemia

Discontinuation of tyrosine kinase inhibitors in chronic myeloid leukemia: Recommendations for clinical practice from the French Chronic Myeloid Leukemia Study Group.

Disease escape with the selective loss of the Philadelphia chromosome after tyrosine kinase inhibitor exposure in Ph-positive acute lymphoblastic leukemia

Factors predicting molecular and cytogenetic response in chronic myeloid leukemia patients treated with imatinib.

Familial myeloid malignancies with germline TET2 mutation

GILZ inhibits the mTORC2/AKT pathway in BCR-ABL(+) cells.

Genome wide SNP array identified multiple mechanisms of genetic changes in Waldenstrom macroglobulinemia.

Genomic characterization of Imatinib resistance in CD34+ cell populations from chronic myeloid leukaemia patients

High frequency of RUNX1 biallelic alteration in acute myeloid leukemia secondary to familial platelet disorder.

Idiopathic hypereosinophilic syndrome: toward a new molecular-targeted therapy and a new cytomorphological and molecular definition

Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia

Incidence and prognostic value of TET2 alterations in de novo acute myeloid leukemia achieving complete remission.

Inhibiting the oncogenic translation program is an effective therapeutic strategy in multiple myeloma.

Isolated tetrasomy 13: a fifth case report of a rare chromosome abnormality associated with poorly differentiated acute myeloid leukemia

Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia

MED13L-related intellectual disability: involvement of missense variants and delineation of the phenotype

MYD88 L265P mutation in Waldenstrom macroglobulinemia.

Mechanisms of genesis of variant translocation in chronic myeloid leukemia are not correlated with ABL1 or BCR deletion status or response to imatinib therapy.

Molecular characterization of the idiopathic hypereosinophilic syndrome (HES) in 35 French patients with normal conventional cytogenetics.

Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP)

Mutations in the ABL kinase domain pre-exist the onset of imatinib treatment.

NUP98 is rearranged in 3.8% of pediatric AML forming a clinical and molecular homogenous group with a poor prognosis

Origin of resistance to Imatinib mesylate: lessons learned from this experience

RUNX1 DNA-binding mutations and RUNX1-PRDM16 cryptic fusions in BCR-ABL+ leukemias are frequently associated with secondary trisomy 21 and may contribute to clonal evolution and imatinib resistance.

Refinement of 1p36 alterations not involving PRDM16 in myeloid and lymphoid malignancies

Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment.

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

TP53 mutation and its prognostic significance in Waldenstrom's Macroglobulinemia

Targeting MYC in multiple myeloma

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

The BCR-ABLT315I mutation compromises survival in chronic phase chronic myelogenous leukemia patients resistant to tyrosine kinase inhibitors, in a matched pair analysis

The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma

The lymphoid variant of hypereosinophilic syndrome: study of 21 patients with CD3-CD4+ aberrant T-cell phenotype

The molecular anatomy of the FIP1L1-PDGFRA fusion gene

The prognosis impact of BCR-ABL P-loop mutations: worse or not worse?

WAGR syndrome and congenital hypothyroidism in a child with a Mosaic 11p13 deletion.

[Cytogenetics and molecular genetics in myelofibrosis with myeloid metaplasia and polycythemia vera]